-
Nature Cancer: EZH2 inhibitor + PD-1 inhibitor to enhance the therapeutic effect of prostate cancer
Time of Update: 2021-05-09
Next, the research team used the B6-HiMYC-PCa transgenic tissue transplantation mouse model and found that EZH2 inhibition or PD-1 treatment alone did not show anti-tumor activity, but the combination therapy produced significant therapeutic effects.
-
[Phase 6] Prostate Cancer Standardized Diagnosis and Treatment Courses-Clinical Trials of Prostate Cancer
Time of Update: 2021-05-09
The sixth "Prostate Cancer Standardized Diagnosis and Treatment Course", the sixth period is the "Clinical Trials of Prostate Cancer" brought by Professor Wang Xuegang from the First Affiliated Hospital of Xiamen University: Click to watch the highlights video!
-
Prostate Cancer Standardized Diagnosis and Treatment Courses——Full-process Standardized Management of Prostate Cancer
Time of Update: 2021-04-28
The fifth "Prostate Cancer Standardized Diagnosis and Treatment Course", the fifth is the "Full-process Standardized Management of Prostate Cancer" brought by Professor Guo Gang from the PLA General Hospital: Click to watch the highlights video!
-
Clinical essentials | Shock wave lithotripsy of upper ureteral calculi
Time of Update: 2021-04-27
Figure 1 The target setting of shock wave focus when SWL is used to treat incarcerated ureteral stones abroad, but the author holds a different view: the upper ureter swings up and down due to the influence of respiration.
-
The nemesis of advanced bladder cancer is here: Tuoyi® (Treprizumab) has been approved for new indications!
Time of Update: 2021-04-24
The results showed that among the 136 patients with locally advanced or metastatic urothelial cancer who had failed platinum-containing chemotherapy, including neoadjuvant or adjuvant chemotherapy, had progressed within 12 months, the overall objective response rate (ORR) of the population was 27.
-
Can the application of transdermal estrogen preparations in patients with prostate cancer achieve lower cardiovascular toxicity
Time of Update: 2021-04-24
? This article from the NEJM meta journals (NEJM Journal Watch) Does Transdermal Estrogen Therapy for Prostate Cancer Decrease Cardiovascular Toxicities percutaneous take estrogen therapy for prostate cancer reduces the possibility of cardiovascular toxicity comment author: Robert Dreicer, MD, MS, MACP, FASCO late Or patients with metastatic prostate cancer who use transdermal estrogen preparations or luteinizing hormone releasing hormone (LHRH) agonists in androgen deprivation treatment have similar cardiovascular outcomes.
-
FDA accelerates approval of sacituzumab govitecan for the treatment of advanced urothelial cancer
Time of Update: 2021-04-24
S. Food and Drug Administration (FDA) accelerated the approval of the Trop-2 antibody conjugate sacituzumab govitecan for patients who have previously received platinum-containing chemotherapy and PD-1/PD-L1 inhibitor treatment Patients with locally advanced or metastatic urothelial cancer.
-
Hengrui Medicine's Class 1 new drug SHR8008 Capsule's second indication was approved for clinical use
Time of Update: 2021-04-24
Recently, Hengrui Medicine announced that its class 1 new drug SHR8008 capsules has been approved by the National Medical Products Administration to carry out a phase III clinical trial for the treatment of acute vulvovaginal candidiasis.
-
Dr. Xu Xianglai from Shanghai Zhongshan Hospital: Prostate stent has become a new choice for refractory urinary retention
Time of Update: 2021-04-23
Prostate stent application history At present, the Department of Urology, Zhongshan Hospital Affiliated to Fudan University has performed 29 cases of Memokath prostate stent implantation, and the operation time is 20-30 minutes.
-
Dialogue with Professor Ye Lefu: Abiraterone brings new "life" to prostate cancer patients|The power of "Ze"
Time of Update: 2021-04-23
As an expert in urology at Fujian Provincial Hospital, Professor Ye Lefu has rich experience in diagnosis and treatment of various urinary diseases, especially prostate cancer.
Professor Ye Lefu introduced that most of the prostate cancer patients in the Department of Urology of Provincial Hospitals are middle-advanced patients, and relatively few early-stage patients.
-
The first indication has just been corrected, and the FDA has accelerated the approval of Trodelvy's second indication-bladder cancer
Time of Update: 2021-04-23
Recently (April 13, 2021), Gilead announced that the FDA has accelerated its approval of a new indication for its targeted Trop-2-ADC drug Trodelvy (sacituzumab govitecan-hziy)-locally advanced or metastatic urothelial cancer.
-
How to predict the 10-year mortality risk of patients with localized prostate cancer?
Time of Update: 2021-04-21
This study sought to determine the pre-treatment patient reporting factors to assess the 10-year risk of death from other causes in patients newly diagnosed with localized prostate cancer.
-
Clinical Essentials | Shock Wave Lithotripsy for Middle Ureteral Stones
Time of Update: 2021-04-21
In the early stage, due to the stone positioning and impact technology, it was inconvenient to use the HM3 sink type first-generation shock wave lithotripter to treat the middle ureteral calculi.
-
IMvigor010 study: What is the effect of adjuvant immunotherapy for muscular invasive urothelial carcinoma?
Time of Update: 2021-04-20
The patients were randomly assigned 1:1 to receive 1200 mg of atilizumab (Q3W, at most 1 year) for adjuvant treatment or observation.
9 months, and the median DFS of the atilizumab group and observation group were 19.
-
Nat Comm | Huang Haojie's team reveals a new mechanism of resistance in prostate cancer
Time of Update: 2021-04-20
Since the histone acetylation modification H3K27ac was significantly up-regulated in these atypically activated gene sites of AR, the researchers further demonstrated that enzalutamide-resistant prostate cancer organoids (Organoid) and patient-derived xenograft tumors (PDX) They were highly sensitive to NEO2734, a dual inhibitor NEO2734 that recognizes the transcriptional regulator BET and CBP/p300 protein that recognizes H3K27ac acetylation modification.
-
The study of enzalutamide PROSPER is based on post-hoc analysis of different dimensions
Time of Update: 2021-04-18
01Abstract 84Prosper study based on age and region post-mortem analysis: enzalutamide + ADT for the OS and safety of nmCRPC patients 1 previous reports on PROSPER studies showed that enzalutamide + androgen deprivation therapy (ADT) Compared with placebo+ADT, it can significantly improve the metastasis-free survival (MFS) and overall survival (OS) of patients with nmCRPC with rapid PSA elevation.
-
2021 AACR | First-line immunotherapy: New hope for patients with urothelial carcinoma with high PD-L1 expression!
Time of Update: 2021-04-18
This meeting reported the results of the second interim OS analysis of group B versus group C, including patients who were not suitable for cisplatin.
-
In 2020, 1 billion treprisumab was sold, and the third indication was "taken" in China
Time of Update: 2021-04-18
On April 7, Junshi Biologics independently developed a recombinant humanized anti-PD-1 monoclonal antibody injection, teriplizumab (trade name: Tuoyi®) for the new indications to be marketed and approved by the State Food and Drug Administration.
-
2021 AACR | Urothelial cancer immunotherapy: which one is better than a single agent or a combination?
Time of Update: 2021-04-18
Conclusion: The exploratory analysis of the IMvigor130 study update OS results showed that first-line treatment with atilizumab can bring survival benefits to patients with PD-L1 IC2/3 and cisplatin-intolerant metastatic urothelial cancer.
-
Clinical essentials | Shock wave lithotripsy of upper ureteral calculi
Time of Update: 2021-03-27
Figure 1 The target setting of shock wave focus when SWL is used to treat incarcerated ureteral stones abroad, but the author holds a different view: the upper ureter swings up and down due to the influence of respiration.
